The International Journal of Tuberculosis and Lung Disease Impact Factor & Information

Publisher: International Union against Tuberculosis and Lung Disease, International Union Against Tuberculosis and Lung Disease

Journal description

The International Journal of Tuberculosis and Lung Disease is the official publication of the International Union Against Tuberculosis Lung Disease (IUATLD). It is distributed in over 165 countries world-wide to physicians, health-workers, researchers, professors, students and decision-makers including public health centres, medical, university and pharmaceutical libraries, hospitals, clinics, foundations and institutions. Published principally in English with French and Spanish summaries, selected articles are translated into French, and a Chinese version is distributed three times per year to 4000 colleagues in China. Plans are also underway for versions in Russian and Spanish. The IJTLD is the reference for clinical research and epidemiological studies on tuberculosis. It is also the only peer-reviewed journal dedicated to lung health worldwide, including articles on non-tuberculosis-related respiratory diseases such as asthma, acute respiratory infection, COPD and the hazards of tobacco and pollution - all topics that reflect the wide scope of the activities of the IUATLD and its members.

Current impact factor: 2.32

Impact Factor Rankings

2015 Impact Factor Available summer 2016
2014 Impact Factor 2.315
2013 Impact Factor 2.756
2012 Impact Factor 2.61
2011 Impact Factor 2.731
2010 Impact Factor 2.557
2009 Impact Factor 2.548
2008 Impact Factor 2.304
2007 Impact Factor 2.24
2006 Impact Factor 2.035
2005 Impact Factor 1.456
2004 Impact Factor 1.484
2003 Impact Factor 1.634
2002 Impact Factor 1.888
2001 Impact Factor 1.737
2000 Impact Factor 2.011
1999 Impact Factor 1.628
1998 Impact Factor 1.233
1997 Impact Factor

Impact factor over time

Impact factor

Additional details

5-year impact 2.25
Cited half-life 6.50
Immediacy index 0.53
Eigenfactor 0.02
Article influence 0.77
Website International Journal of Tuberculosis & Lung Disease website
ISSN 1027-3719
OCLC 36489431
Material type Periodical, Internet resource
Document type Journal / Magazine / Newspaper, Internet Resource

Publisher details

International Union Against Tuberculosis and Lung Disease

  • Pre-print
    • Author cannot archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • On open access repositories
    • Authors version, including all modifications from peer-review
    • Publisher's version/PDF cannot be used
    • Authors to notify Editorial office on submission
    • Publisher copyright and source must be acknowledged
  • Classification

Publications in this journal

  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To refine and evaluate a recently published radiological disease severity score for the prediction of month 2 and end of treatment outcomes in pulmonary tuberculosis (TB). Radiological extent of disease has been linked to early and late outcomes of anti-tuberculosis treatment, but no validated tools are available to quantify this parameter.DESIGN: We enrolled 449 adult, human immunodeficiency virus negative participants with smear- or culture-proven TB from three TB biomarker studies in Cape Town, South Africa. Full-size posteroanterior baseline chest X-rays (CXRs) were evaluated by two clinicians after standardising the published scoring method and the predictive ability assessed for month 2 and final treatment outcomes.RESULTS: Baseline CXR scores were significantly different in the favourable and unfavourable outcome groups; however, the predictive ability for outcomes at all time points was poor (ROC area under curve 0.68). Inter-reader reliability was high (r = 0.86, P CONCLUSION: Standardised application of a CXR score derived from the presence of cavities and overall extent of parenchymal disease in active TB showed good inter- and intrareader reliability. Scores differed significantly in treatment outcome groups, but did not allow accurate outcome prediction.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0098
  • [Show abstract] [Hide abstract]
    ABSTRACT: SETTING: Drug susceptibility testing (DST) is recommended in Kenya to identify multidrug-resistant tuberculosis (MDR-TB) in persons registered for tuberculosis (TB) retreatment. DST is performed at a central laboratory with a two-step growth-based process and a regional laboratory with a simultaneous molecular- and growth-based process.OBJECTIVE: To compare proportions of retreatment cases who underwent DST and turnaround times for hospitals referring to the central vs. regional laboratory.DESIGN: Cases were persons registered for TB retreatment from 1 January 2012 to 31 December 2013. Records of 11 hospitals and 7 hospitals referring patients to the regional and central laboratories, respectively, were reviewed.RESULTS: Respectively 238/432 (55%) and 88/355 (25%) cases from hospitals referring to the regional and central laboratories underwent DST. The mean time from case registration to receipt of DST results and initiation of MDR-TB treatment was quicker in hospitals referring to the regional laboratory. The time required for the transportation of specimens, specimen testing and receipt of DST results at hospitals was shorter for the regional laboratory (P CONCLUSION: Testing was faster and more complete at hospitals referring to the regional laboratory. A comprehensive review of MDR-TB detection in Kenya is required to increase the proportion of cases receiving DST.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0328
  • [Show abstract] [Hide abstract]
    ABSTRACT: Drug-resistant tuberculosis (DR-TB), including multi- and extensively drug-resistant TB, is posing a significant challenge to effective treatment and TB control worldwide. New progress has been made in our understanding of the mechanisms of resistance to anti-tuberculosis drugs. This review provides an update on the major advances in drug resistance mechanisms since the previous publication in 2009, as well as added information on mechanisms of resistance to new drugs and repurposed agents. The recent application of whole genome sequencing technologies has provided new insight into the mechanisms and complexity of drug resistance. However, further research is needed to address the significance of newly discovered gene mutations in causing drug resistance. Improved knowledge of drug resistance mechanisms will help understand the mechanisms of action of the drugs, devise better molecular diagnostic tests for more effective DR-TB management (and for personalised treatment), and facilitate the development of new drugs to improve the treatment of this disease.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0389
  • [Show abstract] [Hide abstract]
    ABSTRACT: SETTINGS: A tertiary referral centre in South Korea.OBJECTIVE: To investigate the incidence, clinical characteristics and outcomes of late paradoxical response (>4 months after the initiation of anti-tuberculosis treatment) during and after anti-tuberculosis treatment in non-human immunodeficiency virus (HIV) infected patients with lymph node tuberculosis (TB).DESIGN: We retrospectively reviewed the medical records of non-HIV-infected patients with lymph node TB between 1997 and 2007, and prospectively enrolled patients with newly diagnosed lymph node TB between 2008 and 2013.RESULTS: Of 467 patients with confirmed and probable lymph node TB, 83 (18%) displayed a paradoxical response: 57 of these (69%) were classified as early and 26 (31%) as late paradoxical response. Patients with late paradoxical response (median 12 months) received more prolonged anti-tuberculosis treatment than those with early (median 9 months, P P CONCLUSIONS: Paradoxical response presents late in about one third of non-HIV-infected patients with lymph node TB who experience a response. Although anti-tuberculosis treatment is commonly prolonged in patients with late paradoxical response, post-treatment lymph node enlargement is more frequent in these patients.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0257

  • The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0580

  • The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0429

  • The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0597
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND AND OBJECTIVE: Patients with loculated tuberculous pleurisy (TBP) treated with urokinase suffer less from residual pleural thickening (RPT) than those treated with simple drainage. However, the role of intrapleural urokinase in free-flowing TBP patients remains unclear.METHODS: A total of 318 patients with presumed TBP were screened. The final 171 patients who participated in the study were randomly allocated to the urokinase group (n = 86) and the control group (n = 85). Personalised doses of urokinase were infused via a catheter. This procedure was repeated every 24 h until the volume of pleural fluid obtained was less than 50 ml after three injections. Changes in lung function and pleural thickening were recorded and compared between both groups periodically for 24 weeks.RESULTS: Seven patients (9.1%) had restrictive functional sequelae in the control group, while no patient in the urokinase group suffered from sequelae (P P P CONCLUSIONS: Patients with free-flowing TBP treated with urokinase suffered less from RPT than those treated with drainage.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0128

  • The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0787
  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND: The outcome of anti-tuberculosis treatment varies according to patient factors.OBJECTIVE: To retrospectively identify risks related to the extension of time to negative sputum culture (Tn) and to determine their clinical significance.DESIGN: Patients with bacilli susceptible to isoniazid and rifampicin who received initial standard treatment without cessation were recruited into the study. A total of 630 consecutive in-patients were included in the risk development analysis (development cohort) and another 611 consecutive in-patients in the risk validation analysis (validation cohort).RESULTS: Univariate analysis showed that Tn was related to sex, body mass index (BMI), white blood cell count (WBC), serum albumin, fasting blood sugar, haemoglobin A1c, C-reactive protein and total cholesterol levels and sputum smear positivity (SSP). Multivariate analysis showed that BMI, WBC and SSP were significant risk factors related to extended Tn. Optimal cut-offs of BMI and WBC for predicting good (Tnn  46 days) according to each risk were determined by receiver operating characteristics analysis. Risks were verified with the validation cohort. Tn increased according to the number of risks; the median Tn for patients with three risks was 21 days longer than that of patients with none.CONCLUSION: The nutritional state of a TB patient can be used to predict Tn.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.14.0963
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To determine whether pulmonary changes on computed tomography (CT) are helpful in differentiating between pleural tuberculosis (TB) and non-tuberculous pleural infectionMATERIALS AND METHODS: We retrospectively reviewed CT scans of patients with pleural tuberculous and non-tuberculous empyema, focusing on pulmonary changes such as consolidation, ground glass opacity, interlobular septal thickening, cavitation, abscess and presence and distribution of micronodules. We also assessed the presence of loss of overlying pleural integrity, peripheral bronchopleural fistula and lymphadenopathy.RESULTS: We evaluated 65 patients with pleural TB and 43 with empyema. CT findings of pleural TB differed significantly from those of empyema with interlobular septal thickening (P = 0.022) and micronodules with subpleural, peribronchovascular and septal distribution (P P CONCLUSION: Interlobular septal thickening and micronodules with perilymphatic distribution are characteristic CT findings of pleural TB but not empyema. Presence of subpleural abscess and loss of pleural integrity or peripheral bronchopleural fistula are highly suggestive of empyema.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0092
  • [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: To determine the diagnostic accuracy of tuberculosis (TB) nucleic acid amplification tests (NAATs) in urine samples for individuals with active pulmonary tuberculosis (PTB).DESIGN: Systematic review and meta-analysis. Electronic databases and reference lists were searched without age or setting restrictions up to May 2015. Eligible articles examined Mycobacterium tuberculosis NAATs in urine samples for PTB diagnosis in patients with sputum culture as the reference standard, and reported sufficient data to separately calculate sensitivity or specificity.RESULTS: Eight studies, including 1212 participants from seven countries with a mean age ranging from 28 to 48 years, were included. Polymerase chain reaction (PCR) with insertion sequence (IS) 6110, rpoB or cfp32/hf6 as gene targets was used for NAATs. The pooled sensitivity and specificity was respectively 0.55 (95%CI 0.36–0.72) and 0.94 (95%CI 0.78–0.99), with slightly higher sensitivity in human immunodeficiency virus positive individuals, at 0.59 (95%CI 0.20–0.89). Sensitivity was higher in sputum microscopy-positive than -negative individuals. Storage temperatures below −70°C, centrifuge speed 6110 increased sensitivity on meta-regression.CONCLUSIONS: Urine M. tuberculosis PCR for active PTB diagnosis had high specificity but modest sensitivity (55%). Optimizing specimen handling, gene targets or PCR techniques may improve diagnostic accuracy. Reproducibility data are needed.
    The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0209

  • The International Journal of Tuberculosis and Lung Disease 11/2015; 19(11). DOI:10.5588/ijtld.15.0782

  • The International Journal of Tuberculosis and Lung Disease 10/2015; 19(10). DOI:10.5588/ijtld.15.0419